CHF Solutions

CHF Solutions is an early stage company focused on commercializing the Aquadex FlexFlow system. Our objective is to improve the quality of life for patients with heart failure and related conditions, such as fluid overload. At CHF Solutions, we are committed to the relentless pursuit of identifying and developing innovative solutions to address unmet clinical needs with the goal of benefiting patients, medical practitioners, and the broader healthcare community.

Aquadex FlexFlow System

The Aquadex FlexFlow system is designed to safely, effectively, and predictably remove excess fluid (primarily excess salt and water) from patients suffering from fluid overload who have failed diuretic therapy. With the Aquadex FlexFlow, medical practitioners can specify and control the amount of fluid to be extracted at a safe, predictable, and effective rate. The Aquadex FlexFlow has been shown to have no clinically significant impact on electrolyte balance, blood pressure or heart rate.¹

The Aquadex FlexFlow is indicated for temporary (up to 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy; and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom have received training in extracorporeal therapies.

To learn more about the Aquadex FlexFlow system, click here

Clinical Evidence

Ultrafiltration (UF) is a method for removing excess salt and water in fluid overloaded patients with heart failure and other related conditions. Several trials including SAFE, the preliminary safety and efficacy study, demonstrated fluid removal goals were achieved in 92% of patients. The RAPID-HF and UNLOAD studies also demonstrated clinical benefit of UF as compared diuretics. The UNLOAD study showed that patients had 38% greater weight loss, 50% reduction in total number of re-hospitalizations, 52% reduction in Emergency Department or clinic visits, and 63% total reduction in days re-hospitalized.

The CARRESS trial showed a rise in creatinine among renal patients on a fixed UF treatment strategy as compared to diuretics, although levels normalized at 7 days post treatment with no difference in body weight, re-hospitalization rates or mortality between the two approaches.

For more information on the Aquadex FlexFlow system clinical evidence and to access past studies, journal articles, and presentations, please visit the clinical evidence section of the website.